

CVD: risk assessment and reduction, including lipid modification.

Information Sharing Event
17th April 2023

NICE National Institute for
Health and Care Excellence



Purpose of today's event

- To provide an overview of work to:
 - Update NICE guideline CG181 (Cardiovascular disease: risk assessment and reduction, including lipid modification)
 - Develop an indicator on treatment target (s) for secondary prevention
- To describe the approach being taken to this work
- To share the key dates and timelines for stakeholders to engage with consultation
- Opportunity for questions.

NICE staff in attendance

- Eric Power – Programme Director (chair)
- Bhash Naidoo – Senior Technical Adviser, Health Economics
- Catrina Charlton – Guideline Commissioning Manager
- Mark Minchin – Associate Director
- Jasdeep Hayre – Associate Director, Health Technology Assessment [industry event only]
- Craig Grime – Technical Adviser

NICE National Institute for
Health and Care Excellence

NICE guideline on CVD

May 2023 update



- What is the most effective risk assessment tool?
- Lifestyle modifications for the primary and secondary prevention of CVD
- Statin therapy for the primary and secondary prevention of CVD



- Consultation on draft recommendations - 12th Jan 2023 to 2nd Feb 2023



- Final guidance expected - 17th May 2023

NICE guideline on CVD

September 2023 update



- In people with established cardiovascular disease, when and to what target should lipid modification therapy be escalated?



- Consultation on draft recommendations and draft indicator
22nd June 2023 to 5th July 2023



- Final guidance expected – 22nd September 2023

Lipid modification

NICE indicator treatment target, secondary prevention



- An indicator underpinned by NICE guidance that can be used in the QOF
- Likely incorporate a non-HDL cholesterol and LDL-cholesterol option



- Consultation on draft indicator – 22nd June 2023 to 5th July 2023



- Final indicator expected – 22nd September 2023

Treatment target for secondary prevention

Review protocol

Appendix A: Review protocol

Review protocol for escalation of lipid modification therapy for secondary prevention of cardiovascular disease (CVD)

ID	Field	Content
1.	Review title	Escalation of lipid modification therapy for secondary prevention of CVD
2.	Review question	In adults with CVD requiring escalation of therapy beyond statins, what is the effectiveness of lipid-lowering therapy?
3.	Objective	To provide evidence on lipid lowering, CVD event risk reduction achieved, and adverse events experienced during escalation of lipid modification therapy to support the identification of a target for secondary prevention of CVD. This review will not be considering sequencing of treatment options listed in the interventions.
4.	Searches	Key papers: <ul style="list-style-type: none"> • IMPROVE-IT • FOURIER • ODYSSEY OUTCOMES • ORION-10 and -11 • Cochrane review on Ezetimibe • Cochrane review on PCSK9 monoclonals <p>The following databases will be searched:</p> <ul style="list-style-type: none"> • Cochrane Central Register of Controlled Trials (CENTRAL) • Cochrane Database of Systematic Reviews (CDSR) • Embase • MEDLINE • Epistemonikos

5.	Condition or domain being studied	Cardiovascular disease
6.	Population	<p>Inclusion:</p> <ul style="list-style-type: none"> • Adults (aged 18 years and older) with CVD. <ul style="list-style-type: none"> ◦ Studies that include ≥80% participants with CVD (or presenting subgroup data for those with CVD) will be preferentially included. ◦ If insufficient data are available from CVD populations, studies including mixed populations with and without CVD (50-79% CVD) will be considered for inclusion. This will be decided separately for each comparison. <p>CVD is defined as including people with/requiring the following:</p> <ul style="list-style-type: none"> • Ischaemic stroke • Transient ischaemic attack • Myocardial infarction • Coronary heart disease (for example unstable and stable angina) • Peripheral artery disease • Coronary or non-coronary arterial revascularisation procedures <p>Exclusion:</p> <ul style="list-style-type: none"> • Children aged under 18 years of age.

Treatment target for secondary prevention

Economic plan

2 List of modelling questions

Review questions by scope area	Treatment target for secondary prevention: In people with established cardiovascular disease, when and to what target should lipid modification therapy be escalated?
Population	Adults who have CVD and are on lipid modification treatment with a statin.
Interventions and comparators considered for inclusion	People whose cholesterol level is above the target despite being on a statin will receive further treatments. Different targets for cholesterol (non-HDL or LDL) in primary care will be compared to identify the ones that are the most cost-effective.
Perspective	NHS and personal social services
Outcomes	QALY
Type of analysis	Cost-utility analysis
Modelling software	Excel
Issues to note	

Thank you